Administering a clinically relevant “low dose” of a compound known to inhibit mTORC1 activity called RAD001, Joseph et al. showed that in some muscles that would have undergone sarcopenia, the mass of that muscle was increased, there was histological evidence of improved muscle morphology (e.g., increases in fiber cross‐sectional area, decreased frequency of centrally placed nuclei), reduced expression of putative atrophy genes (e.g., MuRF1 and MT1), and increases in levels of protein markers of autophagy (which decline with sarcopenia) (Joseph et al., 2019). This evidence concerns the gene TRIM63 and sarcopenia.